Immune-modified Glasgow prognostic score: A new prognostic marker for head and neck cancer

Background The modified Glasgow prognostic score (mGPS) includes C-reactive protein and serum albumin levels and is a useful prognostic tool for malignant tumors. The immune system affects cancer progression and recurrence and treatment response. We hypothesized that increasing the lymphocyte count improves mGPS, and we created a new prognostic marker termed immune-mGPS (imGPS). Methods This study included 461 patients with head and neck squamous cell carcinoma (HNSCC). The imGPS was calculated as the conventional mGPS with one additional point for a low lymphocyte count (<1250/mu L). Results Addition of the lymphocyte count to mGPS significantly increased the area under the time-dependent receiver operating characteristic curve for overall and progression-free survivals. The added predictive abilities of this tool were supported by improvement in both net reclassification and integrated discrimination. Conclusion imGPS is a more accurate predictor of clinical outcome in patients with HNSCC than mGPS.

Automated summary

In this study, we investigated the prognostic role of immune-mGPS (imGPS) in patients with head and neck squamous cell carcinoma (HNSCC) and found that imGPS is a more accurate predictor compared to the conventional mGPS.